X-Tosis develops first-in-class mitochondrial therapeutics targeting the root causes of neurodegeneration. Their VDAC1-modulating compounds aim to restore mitochondrial function and prevent neuronal death in conditions like Alzheimer's and Parkinson's disease. The platform utilizes precision biomarkers for patient selection, treatment, and monitoring of these neurodegenerative diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Alzheimer's and Parkinson's diseases are characterized by neurodegeneration driven by mitochondrial dysfunction. Current treatments do not effectively target the underlying mechanisms of neuronal cell death and inflammation associated with these diseases. This results in limited therapeutic options for halting disease progression and improving patient outcomes.
Solution
X-Tosis is developing a novel therapeutic approach targeting VDAC1 oligomerization, a key factor in mitochondrial dysfunction and subsequent neurodegeneration in Alzheimer's and Parkinson's diseases. By inhibiting VDAC1 oligomerization, X-Tosis aims to prevent mitochondrial damage, reduce neuronal cell death, and mitigate inflammation within the brain. This targeted intervention seeks to halt or slow the progression of neurodegenerative diseases by preserving neuronal health and optimizing cellular function. The company's compounds are designed to address the root causes of these diseases, offering a potential disease-modifying therapy.
Target Audience
The primary target audience includes patients diagnosed with Alzheimer's and Parkinson's diseases, as well as healthcare providers specializing in neurology and neurodegenerative disorders.
Features
- Compounds designed to inhibit VDAC1 oligomerization.
- Targeted approach to prevent mitochondrial dysfunction.
- Aims to reduce neuronal cell death and inflammation.
- Potential to halt or slow the progression of Alzheimer's and Parkinson's diseases.